Mechanisms of resistance to quinolones: Target alterations, decreased accumulation and DNA gyrase protection

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 5, 2003, Pages 1109-1117

  Ruiz, Joaquim ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

DNA gyrase; Efflux pumps; qnr; Quinolone resistance; Topoisomerase IV

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; MARBOFLOXACIN; MEMBRANE PROTEIN; MOXIFLOXACIN; NADIFLOXACIN; NALIDIXIC ACID; PORIN; QNR PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REPRESSOR PROTEIN; SALICYLIC ACID DERIVATIVE; SPARFLOXACIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CELL MEMBRANE PERMEABILITY; CLINICAL PRACTICE; DRUG ACCUMULATION; DRUG TARGETING; DRUG TRANSPORT; DRUG USE; ENZYME ACTIVITY; GENE MUTATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; VETERINARY MEDICINE;

ANTI-INFECTIVE AGENTS; BACTERIA; DNA GYRASE; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, BACTERIAL; HUMANS; QUINOLONES;

EID: 0038440791     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg222     Document Type: Review

References (95)

1. Lescher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H. & Brundage, R. P. (1962). 1,8-Naphthyridine derivatives: a new class of chemotherapy agents. Journal of Medicinal and Pharmaceutical Chemistry 5, 1063-8.
2. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1996). Susceptibility of anaerobic bacteria to trovafloxacin: comparison with other quinolones and non-quinolone antibiotics. Infectious Diseases in Clinical Practice 5, Suppl. 3, S101-9.
3. Roychoudhury, S., Twinem, T. L., Makin, K. M., McIntosh, E. J., Ledoussal, B. & Catrenich, C. E. (2001). Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 48, 29-36.
4. Vila, J., Ruiz, J., Sanchez, F., Navarro, F., Mirelis, B., Jiménez de Anta, M. T. et al. (1999). Investigation of quinolone resistance development of an Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrobial Agents and Chemotherapy 43, 161-2.
5. Davis, R., Markham, A. & Balfour, J. A. (1996). Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 6, 1019-74.
6. Acar, J. F. & Goldstein, F. W. (1997). Trends in bacterial resistance to fluoroquinolones. Clinical Infectious Diseases 24, Suppl. 1, S67-S73.
7. Grange, J. D., Roulot, D., Pelletier, G., Pariente, E. A., Denis, J., Ink, O. et al. (1998). Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. Journal of Hepatology 29, 430-6.
8. Solomon, D. H., Van Houten, L., Glynn, R. J., Baden, L., Curtis, K., Schrager, H. et al. (2001). Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Archives of Internal Medicine 161, 1897-902.
9. Hart, C. A. & Kariuki, S. (1998). Antimicrobial resistance in developing countries. British Medical Journal 317, 647-50.
10. Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T. & Tomizawa, J. I. (1977). Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proceedings of the National Academy of Sciences, USA 74, 4772-6.
11. Khodursky, A. B., Zechiedrich, E. L. & Cozzarelli, N. R. (1995). Topoisomerase IV is a target of quinolones in Escherichia coli. Proceedings of the National Academy of Sciences, USA 92, 11801-5.
12. Sugino, A., Peebles, C. I., Krenzer, K. N. & Cozzarelli, N. R. (1977). Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proceedings of the National Academy of Sciences, USA 74, 4767-71.
13. Horowitz, D. S. & Wang, J. C. (1987). Mapping the active site tyrosine of Escherichia coli DNA Gyrase. Journal of Biological Chemistry 262, 5339-44.
14. Drlica, K. & Zhao, X. (1997). DNA Gyrase, Topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews 61, 377-92.
15. Pan, X.-S. & Fisher, L. M. (1997). Targeting of DNA Gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrobial Agents and Chemotherapy 41, 471-4.
16. Ruiz, J., Sierra, J. M., Jiménez de Anta, M. T. & Vila, J. (2001). Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro. International Journal of Antimicrobial Agents 118, 107-12.
17. Takei, M., Fukuda, H., Kishii, R. & Hosaka, M. (2001). Target preference of 15 quinolones against Staphylococcus aureus based on antibacterial activities and target inhibition. Antimicrobial Agents and Chemotherapy 45, 3544-7.
18. Nakamura, S., Nakamura, M., Kojima, T. & Yoshida, H. (1989). gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrobial Agents and Chemotherapy 33, 254-5.
19. Everett, M. J., Jin, Y. F., Ricci, V. & Piddock, L. J. V. (1996). Contribution of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrobial Agents and Chemotherapy 40, 2380-6.
20. Vila, J., Ruiz, J., Marco, F., Barceló, A., Goñi, P., Giralt, E. et al. (1994). Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and minimal inhibitory concentration. Antimicrobial Agents and Chemotherapy 38, 2477-9.
21. Yoshida, H., Bogaki, M., Nakamura, M. & Nakamura, S. (1990). Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrobial Agents and Chemotherapy 34, 1271-2.
22. Cambau, E., Bordon, F., Collatz, E. & Gutmann, L. (1993). Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrobial Agents and Chemotherapy 37, 1247-52.
23. Hallett, P. & Maxwell, A. (1991). Novel quinolone-resistant mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins. Antimicrobial Agents and Chemotherapy 35, 335-40.
24. Oram, M. & Fisher, L. M. (1991). 4-Quinolone resistance mutations in the DNA Gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrobial Agents and Chemotherapy 35, 387-9.
25. Tavio, M. M., Vila, J., Ruiz, J., Martin-Sanchez, A. M. & Jiménez de Anta, M. T. (1999). Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli strains. Journal of Antimicrobial Chemotherapy 44, 735-42.
26. Truong, Q. C., Nguyen Van, J. C., Shlaes, D., Gutmann, L. & Moreau, N. J. (1997). A novel, double mutation in DNA Gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Antimicrobial Agents and Chemotherapy 41, 85-90.
27. Yoshida, H., Kojima, T., Yamagishi, J. L. & Nakamura, S. (1988). Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Molecular and General Genetics 211, 1-4.
28. Friedman, S., Lu, T. & Drlica, K. (2001). Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrobial Agents and Chemotherapy 45, 2378-80.
29. Ruiz, J., Gómez, J., Navia, M. M., Ribera, A., Sierra, J. M., Marco, F. et al. (2002). High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease 42, 257-61.
30. Hakanen, A., Kotilainen, P., Jalava, A., Siitonen, A. & Huovinen, P. (1999). Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. Journal of Clinical Microbiology 37, 3572-7.
31. Reyna, F., Huesca, M., Gonzalez, V. & Fuchs, L. Y. (1995). Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistance. Antimicrobial Agents and Chemotherapy 39, 1621-3.
32. Bachoual, R., Ouabdesselam, S., Mory, F., Lascols, C., Soussy, C.-J. & Tankovic, J. (2001). Single or double mutational alterations of GyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Microbial Drug Resistance 7, 257-61.
33. Ruiz, J., Goñi, P., Marco, F., Gallardo, F., Mirelis, B., Jiménez de Anta, M. T. et al. (1998). Increased resistance in Campylobacter jejuni. A genetic analysis of gyrA gene mutation in ciprofloxacin resistant clinical isolates. Microbiology and Immunology 42, 223-6.
34. Ribera, A., Jurado, A., Ruiz, J., Marco, F., Del Valle, O., Mensa, J. et al. (2002). In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine. Diagnostic Microbiology and Infectious Disease 42, 123-8.
35. Valdezate, S., Vindel, A., Baquero, F. & Cantón, R. (1999). Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia. European Journal of Clinical Microbiology and Infectious Diseases 18, 908-11.
36. Ribera, A., Domenech-Sanchez, A., Ruiz, J., Benedí, V. J., Jiménez de Anta, M. T. & Vila, J. (2002). Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in Stenotrophomonas maltophilia. Microbial Drug Resistance 8, 245-51.
37. Valdezate, S., Vindel, A., Echeita, A., Baquero, F. & Canton, R. (2002). Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrobial Agents and Chemotherapy 46, 665-71.
38. Alonso, A. & Martínez, J. L. (1997). Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy 41, 1140-2.
39. Alonso, A. & Martínez, J. L. (2001). Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy 45, 1879-81.
40. Vila, J., Ruiz, J. & Navia, M. M. (1999). Molecular bases of quinolone resistance acquisition in gram-negative bacteria. Recent Research Developments in Antimicrobials and Chemotherapy 3, 323-44.
41. Vila, J., Ruiz, J., Goñi, P., Marcos, M. A. & Jiménez de Anta, M. T. (1995). Mutations in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 39, 1201-3.
42. Ruiz, J., Castro, D., Goñi, P., Santamaria, J. A., Borrego, J. J. & Vila, J. (1997). Analysis of the mechanism of quinolone-resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium. Journal of Medical Microbiology 46, 623-8.
43. Jones, M. E., Sahm, D. F., Martin, N., Scheuring, S., Heisig, P., Thornsberry, C. et al. (2000). Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrobial Agents and Chemotherapy 44, 462-6.
44. Schmitz, F. J., Jones, M. E., Hofmann, B., Hansen, B., Scheuring, S., Luckefarh, M. et al. (1998). Characterization of grlA, grlB, gyrA and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrobial Agents and Chemotherapy 42, 1249-52.
45. Griggs, D. J., Gensberg, K. & Piddock, L. J. V. (1996). Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from human and animals. Antimicrobial Agents and Chemotherapy 40, 1009-13.
46. 2-terminal 83rd amino acid of Escherichia coli GyrA in quinolone-resistance. Microbiology and Immunology 39, 243-7.
47. Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M. & Nakamura, S. (1991). Quinolone resistance-determining region in the DNA Gyrase gyrB gene of Escherichia coli. Antimicrobial Agents and Chemotherapy 35, 1647-50.
48. Ito, H., Yoshida, H., Bogaki-Shonai, M., Niga, T., Hattori, H. & Nakamura, S. (1994). Quinolone-resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 38, 2014-23.
49. Gensberg, K., Jin, Y. F. & Piddock, L. J. V. (1995). A novel gyrB mutation in a quinolone-resistant clinical isolate of Salmonella typhimurium. FEMS Microbiology Letters 132, 57-60.
50. Heisig, P. (1996). Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy 40, 879-85.
51. Kumagai, Y., Kato, J. I., Hoshino, K., Akasaka, T. Sato, K. & Ikeda, H. (1996). Quinolone-resistant mutants of Escherichia coli DNA Topoisomerase IV parC gene. Antimicrobial Agents and Chemotherapy 40, 710-4.
52. Ng, E. Y., Trucksis, M. & Hooper, D. C. (1996). Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA Gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 40, 1881-8.
53. Vila, J., Ruiz, J., Goñi, P. & Jiménez de Anta, M. T. (1996). Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrobial Agents and Chemotherapy 40, 491-3.
54. Chu, Y. W., Houang, E. T. S. & Cheng, A.-F. B. (1998). Novel combination of mutations in the DNA-gyrase and topoisomerase IV genes in laboratory-grown fluoroquinolone-resistant Shigella flexneri mutants. Antimicrobial Agents and Chemotherapy 42, 3051-2.
55. Ince, D. & Hooper, D. C. (2001). Mechanisms and frequency of resistance to gatifloxacin in comparison to AM1121 and ciprofloxacin in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 45, 2755-64.
56. Ruiz, J., Casellas, S., Jiménez de Anta, M. T. & Vila, J. (1997). The region of the parE gene, homologous to the quinolone-resistant determining region of the gyrB gene, is not linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates. Journal of Antimicrobial Chemotherapy 39, 839-40.
57. Breines, D. V., Ouabdesselam, S., Ng, E. Y., Tankovic, J., Shah, S., Soussy, C. J. et al. (1997). Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of Topoisomerase IV. Antimicrobial Agents and Chemotherapy 41, 175-9.
58. Perichon, B., Tankovic, J. & Courvalin, P. (1997). Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 41, 1166-7.
59. Janoir, C., Varon, E., Kitzis, M. D. & Gutmann, L. (2001). New mutation in ParE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrobial Agents and Chemotherapy 45, 952-5.
60. Fournier, B. & Hooper, D. C. (1998). Mutations in topoisomerase IV and DNA-Gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrobial Agents and Chemotherapy 42, 121-8.
61. Chapman, J. S. & Georgopapadokou, N. H. (1988). Routes of quinolone permeation in Escherichia coli. Antimicrobial Agents and Chemotherapy 32, 438-42.
62. Hirai, K., Aoyama, H., Irikura, T., Iyobe, S. & Mitsuhashi, S. (1986). Difference in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrobial Agents and Chemotherapy 29, 535-8.
63. Moniot-Ville, N., Guibert, J., Moreau, N., Acar, J. F., Collatz, E. & Gutmann, L. (1991). Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrobial Agents and Chemotherapy 35, 519-23.
64. Aoyama, H., Sato, K., Kato, T., Hirai, K. & Mitsuhashi, S. (1987). Norfloxacin resistance in a clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 31, 1640-1.
65. Mitsuyama, J., Itoh, Y., Takahata, M., Okamoto, S. & Yasuda, T. (1992). In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis and Salmonella typhimurium. Antimicrobial Agents and Chemotherapy 36, 2030-6.
66. Cohen, S. P., McMurry, L. M., Hooper, D. C., Wolfson, J. S. & Levy, S. B. (1989). Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrobial Agents and Chemotherapy 33, 1318-25.
67. Aleksun, M. N. & Levy, S. B. (1997). Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrobial Agents and Chemotherapy 41, 2067-75.
68. Chou, J. H., Greenberg, J. T. & Demple, B. (1993). Posttranscriptional repression of Escherichia coli OmpF in response to redox stress: positive control of the micF antisense RNA by the soxRS locus. Journal of Bacteriology 175, 1026-31.
69. Nikaido, H. (1996). Multidrug efflux pumps of gram-negative bacteria. Journal of Bacteriology 178, 5833-9.
70. Oethingher, M., Podglajen, I., Kern, W. V. & Levy, S. B. (1998). Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrobial Agents and Chemotherapy 42, 2089-94.
71. Baucheron, S., Imberechts, H., Chaslus-Dancla, E. & Cloeckaert, A. (2002). The AcrAB multidrug transporter plays a major role in high level fluoroquinolone resistance in Salmonella enterica serovar Typhimurium phage type DT204. Microbial Drug Resistance 8, 281-9.
72. Angus, B. L., Carey, A. M., Caron, D. A., Kropinsky, A. M. B. & Hanconck, R. E. W. (1982). Outer membrane permeability in Pseudomonas aeruginosa comparison of a wild-type with an antibiotic-supersusceptible mutant. Antimicrobial Agents and Chemotherapy 21, 299-309.
73. Yoshimura, F. & Nikaido, H. (1982). Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. Journal of Bacteriology 152, 636-42.
74. Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H. & Nishino, T. (2000). Contributions of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 44, 2242-6.
75. Mine, T., Morita, Y., Kataoka, A., Mizushima, T. & Tsuchiya, T. (1999). Expression in Escherichia coli of a new efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 43, 415-7.
76. Zhao, Q., Li, X.-Z., Srikumar, R. & Poole, K. (1998). Contribution of outer membrane efflux protein OprM to antibiotic resistance in Pseudomonas aeruginosa independent of MexAB. Antimicrobial Agents and Chemotherapy 42, 1682-8.
77. Magnet, S., Courvalin, P. & Lambert, T. (2001). Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrobial Agents and Chemotherapy 45, 3375-80.
78. Lin, J., Michel, L. O. & Zhang, Q. (2002). CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrobial Agents and Chemotherapy 46, 2124-31.
79. Putman, M., Van Been, H. W. & Konings, W. L. (2000). Molecular properties of bacterial multidrug transporters. Microbiology and Molecular Biology Reviews 64, 672-93.
80. Nishino, K. & Yamaguchi, A. (2001). Analysis of a complete library of putative drug transporter genes in Escherichia coli. Journal of Bacteriology 183, 5803-12.
81. Yoshida, H., Bogaki, M., Nakamura, S., Ubukata, K. & Konno, M. (1990). Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. Journal of Bacteriology 172, 6942-9.
82. Sierra, J. M., Ruiz, J., Jiménez de Anta, M. T. & Vila, J. (2000). Prevalence of two different genes, encoding NorA, in 23 clinical strains of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 46, 145-6.
83. Ahmed, M., Lyass, L., Markham, P. N., Taylor, S. S., Vasquez-Laslop, N. & Neyfakh, A. A. (1995). Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated. Journal of Bacteriology 177, 3904-10.
84. Gill, M. J., Brenwald, N. P. & Wise, R. (1999). Identification of an efflux pump gene pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 43, 187-9.
85. Guerin, F., Varon, E., Hoi, A. B., Gutmann, L. & Podglajen, I. (2000). Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. Antimicrobial Agents and Chemotherapy 44, 2197-200.
86. Renau, T. E., Léger, R., Yen, R., She, M. E., Flamme, E. M., Sangalang, J. et al. (2002). Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorganic and Medicinal Chemistry Letters 12, 763-6.
87. Ribera, A., Ruiz, J., Jimenez de Anta, M. T. & Vila, J. (2002). Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates. Journal of Antimicrobial Chemotherapy 49, 697-8.
88. Munshi, M. H., Sack, D. A., Hider, K., Ahmed, Z. U., Rahaman, M. M. & Morshed, M. G. (1987). Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 2, 419-21.
89. Panhotra, B. R., Desai, B. & Sharma, P. L. (1985). Nalidixic-acid-resistant Shigella dysenteriae I. Lancet I, 763.
90. Courvalin, P. (1990). Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrobial Agents and Chemotherapy 34, 681-4.
91. Martínez-Martínez, L., Pascual, A. & Jacoby, G. A. (1998). Quinolone resistance from a transferable plasmid. Lancet 351, 797-9.
92. Tran, J. H. & Jacoby, G. A. (2002). Mechanism of plasmid mediated quinolone resistance. Proceedings of the National Academy of Sciences, USA 99, 5638-42.
93. Jacoby, G. A., Chow, N. & Waites, K. B. (2003). Prevalence of plasmid-mediated quinolone resistance. Antimicrobial Agents and Chemotherapy 47, 559-62.
94. Ferrandiz, M. J., Fenoll, A., Linares, J. & De La Campa, A. G. (2000). Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 44, 840-7.
95. Janoir, C., Podglajen, I., Kitzis, M. D., Poyart, C. & Gutmann, L. (1999). In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. Journal of Infectious Diseases 180, 555-8.